**Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation**


**Objective:** To conduct a randomized clinical trial to determine the efficacy of IV amiodarone in patients with out-of-hospital cardiac arrest due to shock-refractory (defined as no ROSC after ≥3 precordial shocks) VF or VT

**Methods:**
- 504 patients; Conducted in Seattle (21 paramedic base stations; 15 hospitals)
- Randomized, double-blinded, placebo-controlled study over 27 months
- Cardiac arrest victims treated by FD (BLS inc AED) until paramedics arrived
- Inclusion Criteria:
  - Adults with non-traumatic out-of-hospital cardiac arrest who had VF or pulseless VT at time of drug administration
  - No ROSC after ≥3 precordial shocks
  - IV access established
  - Paramedics on scene with study drug or placebo
- Eligible patients were intubated, given 1mg Epi IV then either 300mg amio or placebo (diluent-polysorbate 80) in identical unlabeled vials
- Primary end point: admission to hospital bed with a spontaneously perfusing rhythm
- Secondary endpoints: adverse effects, # precordial shocks req after amio/placebo, total duration of resuscitation, need for other antiarrhythmics

**Results:**
- Initial rhythm: 84% VF/VT, 16% asystole/PEA
- Rhythm at time of study-drug admin: 88% VF, 7% VT, 5% not documented
- On average 5 shocks were delivered before study drug administered
- Of 298 pt with ROSC, recipients of amiodarone were significantly more likely to be hypotensive (p=0.04), bradycardic (p=0.004) on arrival to hospital
- 197 pt (39%) survived to hospital admission
  - Pt receiving amio more likely to be resuscitated and admitted to hospital (44% vs 34%, p=0.03); Women benefit more than men (p=0.008)
  - 1.6 adjusted OR (95%CI 1.1-2.4; p=0.02) for survival to admission in recipients of amio vs placebo
- 67 pt (13%) were discharged from hospital
  - Study not powered to detect differences in survival to discharge

**Bottom Line:** Compared with placebo, amiodarone significantly and independently improved the rate of survival to hospital admission after shock-refractory cardiac arrest due to VF or pulseless VT. Benefit observed in all major subgroups, regardless of the presenting arrest rhythm, whether or not there was a transient ROSC before tx, and even if amiodarone was administered late in the course of resuscitation